Shi-Feng Long1, Guo-An Chen2, Mu-Shui Fang3. 1. School of Medicine, Nanchang UniversityJiangxi Province, PR China; Department of Hematology, Affiliated Hospital of Jinggangshan UniversityJiangxi Province, PR China. 2. School of Medicine, Nanchang University Jiangxi Province, PR China. 3. Department of Hematology, Affiliated Hospital of Jinggangshan University Jiangxi Province, PR China.
Abstract
PURPOSE: To explore the role of serum interleukin-16 (IL-16) in the occurrence of multiple myeloma (MM) and after the success chemotherapy and its clinical significance. METHODS: 52 cases of MM patients, 30 cases of AML patients and 30 healthy volunteers from Jan. 2011 to Jan. 2015 were collected in this study. There was 39 MM patients received chemotherapy. Among those, 24 patients received VAD regimen chemotherapy and 15 patients received BD regimen chemotherapy. Serum IL-16, cystatin C (Cys-C), lactate dehydrogenase (LDH) and levels of β2-microglobulin (β2-MG) were detected before and after the therapy of MM patients. And those results were compared to that of patients with acute myelogenous leukemia (AML) and normal people respectively. RESULTS: The levels of serum IL-16, Cys-C, LDH and β2-MG in MM group were remarkably higher than that of normal control. It was of statistical significance of this difference (P<0.05). Levels of serum IL-16, Cys-C and LDH of MM patients who received therapy were all lower than that of patients before therapy. The serum IL-16 and β2-MG of 52 patients by preliminary diagnosis were analyzed through Pearson correlation analysis before they received therapy. The results showed that there was positive correlation between levels of IL-16 and β2-MG (r=0.782, P<0.01). CONCLUSIONS: A high serum IL-16 level detected in newly diagnosed MM patients and its correlation with known factors of disease activity as well as the decrease of IL-16 after chemotherapy suggest that IL-16 may be implicated and a potential therapeutic target for MM.
PURPOSE: To explore the role of serum interleukin-16 (IL-16) in the occurrence of multiple myeloma (MM) and after the success chemotherapy and its clinical significance. METHODS: 52 cases of MMpatients, 30 cases of AMLpatients and 30 healthy volunteers from Jan. 2011 to Jan. 2015 were collected in this study. There was 39 MMpatients received chemotherapy. Among those, 24 patients received VAD regimen chemotherapy and 15 patients received BD regimen chemotherapy. Serum IL-16, cystatin C (Cys-C), lactate dehydrogenase (LDH) and levels of β2-microglobulin (β2-MG) were detected before and after the therapy of MMpatients. And those results were compared to that of patients with acute myelogenous leukemia (AML) and normal people respectively. RESULTS: The levels of serum IL-16, Cys-C, LDH and β2-MG in MM group were remarkably higher than that of normal control. It was of statistical significance of this difference (P<0.05). Levels of serum IL-16, Cys-C and LDH of MMpatients who received therapy were all lower than that of patients before therapy. The serum IL-16 and β2-MG of 52 patients by preliminary diagnosis were analyzed through Pearson correlation analysis before they received therapy. The results showed that there was positive correlation between levels of IL-16 and β2-MG (r=0.782, P<0.01). CONCLUSIONS: A high serum IL-16 level detected in newly diagnosed MMpatients and its correlation with known factors of disease activity as well as the decrease of IL-16 after chemotherapy suggest that IL-16 may be implicated and a potential therapeutic target for MM.
Authors: Aparna Yellapa; Janice M Bahr; Pincas Bitterman; Jacques S Abramowicz; Seby L Edassery; Krishna Penumatsa; Sanjib Basu; Jacob Rotmensch; Animesh Barua Journal: Int J Gynecol Cancer Date: 2012-02 Impact factor: 3.437
Authors: Jian C Qi; Jing Wang; Sravan Mandadi; Kumiko Tanaka; Basil D Roufogalis; Michele C Madigan; Kenneth Lai; Feng Yan; Beng H Chong; Richard L Stevens; Steven A Krilis Journal: Blood Date: 2005-09-06 Impact factor: 22.113
Authors: Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin Journal: J Clin Oncol Date: 2005-04-04 Impact factor: 44.544
Authors: Michael G Alexandrakis; Freda H Passam; Despina S Kyriakou; Anna V Christophoridou; Kostas Perisinakis; Aria Hatzivasili; Andreas Foudoulakis; Elias Castanas Journal: Am J Hematol Date: 2004-02 Impact factor: 10.047